You just read:

RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus

News provided by

Resverlogix Corp.

02 Sep, 2014, 13:30 BST